Any feedback?
Information on EC 2.4.1.102 - beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase
for references in articles please use BRENDA:EC2.4.1.102Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.4.1.102 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferaseIUBMB Comments
The enzyme catalyses the addition of N-acetyl-alpha-D-glucosamine to the core 1 structure of O-glycans forming core 2.
Specify your search results
Word Map
- 2.4.1.102
- o-glycans
- glycosyltransferases
-
sialylated
-
p-selectin
-
o-linked
- selectins
- ligand-1
-
core-2
- psgl-1
- fuct-vii
- st3gals
- medicine
- poly-n-acetyllactosamine
-
sialyl-lewis
-
udp-glcnac:gal
- diagnostics
-
1-3galnac-r
-
polylactosamine
-
alpha2,3-sialyltransferase
- molecular biology
- synthesis
The enzyme appears in viruses and cellular organisms
Reaction Schemes
+
=
+
+
O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein]
=
+
O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
Synonyms
c2gnt, gcnt3, gcnt1, c2gnt-m, c2gnt1, core 2 glcnac-t, c2glcnact-i, c2gnt-l, c2gnt-1, core 2 beta-1,6-n-acetylglucosaminyltransferase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-mucin beta-(1-6)-
-
-
-
-
acetylglucosaminyltransferase, uridine diphosphoacetylglucosamine-mucin beta-(1-6)-, A
-
-
-
-
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3
-
beta-1,6-N-acetylglucosaminyltransferase
beta6-N-acetylglucosaminyltransferase
-
-
-
-
C2GlcNAcT-I
C2GnT
C2GnT-I
c2GnT-M
C2GnT2
core 2 acetylglucosaminyltransferase
-
-
-
-
core 2 beta-1,6 N-acetylglucosaminyltransferase
core 2 beta-1,6-N-acetylglucosaminyltransferase
core 2 beta1,6-N-acetylglucosaminyltransferase
core 2 beta1,6-N-acetylglucosaminyltransferase I
core 2 GlcNAc-T
core 2 N-acetylglucosaminyltransferase
core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type
core 6-beta-GlcNAc-transferase A
-
-
-
-
GCNT1
gcnt3
O-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase I
-
-
-
-
uridine diphosphoacetylglucosamine-mucin beta-(1-6)-acetylglucosaminyltransferase
-
-
-
-
uridine diphosphoacetylglucosamine-mucin beta-(1-6)-acetylglucosaminyltransferase A
-
-
-
-
additional information
core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type
-
core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type
-
-
additional information
core 2 beta6-GalNAc-transferase, EC 2.4.1.102, exists in 2 types, type L and type M, the latter shows an additional core 4 beta6-GalNAc transferase activity
additional information
-
core 2 beta6-GalNAc-transferase, EC 2.4.1.102, exists in 2 types, type L and type M, the latter shows an additional core 4 beta6-GalNAc transferase activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein] = UDP + O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein] = UDP + O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
-
-
-
-
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein] = UDP + O3-{beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl}-L-seryl/threonyl-[protein]
C2GnT operates through an inverting mechanism following a SN2-like reaction in which the enzyme provides a catalytic base that activates the nucleophile (in C2GnT, this is the C6 hydroxyl group from a GalNAc residue) to displace the uridine 5'-diphosphate (UDP) leaving group from the UDP-GlcNAc donor in a concerted process. It is assumed that C2GnT follows the ordered bi-bi catalytic mechanism with the UDP-GlcNAc bindings first, followed by the disaccharide acceptor binding over the nucleotide sugar. Reaction mechanism, quantum mechanical/molecular modeling, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hexosyl group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
UDP-N-acetyl-alpha-D-glucosamine:O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-glycoprotein 6-beta-N-acetyl-D-glucosaminyltransferase (configuration-inverting)
The enzyme catalyses the addition of N-acetyl-alpha-D-glucosamine to the core 1 structure of O-glycans forming core 2.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
87927-97-7
-
95978-15-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
UDP-GlcNAc + (Galbeta1-3GalNAcalpha1-)TAGV
UDP + (Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TAGV
-
pH 7.0, 0.2 mM, 1250% activity
-
-
?
UDP-GlcNAc + 4-nitrophenyl 2-(acetylamino)-2-deoxy-3-O-beta-D-galactopyranosyl-alpha-D-galactopyranoside
UDP + 4-nitrophenyl 2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl-(1-6)-[beta-D-galactopyranosyl-(1-3)]-2-(acetylamino)-2-deoxy-alpha-D-galactopyranoside
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-G-(Galbeta1-3GalNAcalpha1-)TTTPIST-NH2
UDP + Ac-G-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTPIST-NH2
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-G-(Galbeta1->3GalNAcbeta1->)TTTPIST-NH2
UDP + Ac-G-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTPIST-NH2
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + Ac-GT-(Galbeta1-3GalNAcalpha1-)TTPIST-NH2
UDP + Ac-GT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTPIST-NH2
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-GT-(Galbeta1->3GalNAcbeta1->)TTPIST-NH2
UDP + Ac-GT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTPIST-NH2
-
pH 7.0, 0.2 mM, 150% activity
-
-
?
UDP-GlcNAc + Ac-GTT-(Galbeta1-3GalNAcalpha1-)TPIST-NH2
UDP + Ac-GTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPIST-NH2
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-GTT-(Galbeta1->3GalNAcbeta1->)TPIST-NH2
UDP + Ac-GTT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TPIST-NH2
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1-3GalNAcalpha1-)TTTGIST-NH2
UDP + Ac-P-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTGIST-NH2
-
pH 7.0, 0.2 mM, 50% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1-3GalNAcalpha1-)TTTPIST-NH2
UDP + Ac-P-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTTPIST-NH2
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1->3GalNAcbeta1->)TTTGIST-NH2
UDP + Ac-P-(Galbeta1->3[GlcNAcbeta1->6]GalNAcbeta1->)TTTGIST-NH2
-
pH 7.0, 0.2 mM, 200% activity
-
-
?
UDP-GlcNAc + Ac-P-(Galbeta1->3GalNAcbeta1->)TTTPIST-NH2
UDP + Ac-P-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTTPIST-NH2
-
pH 7.0, 0.2 mM, 175% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1-3GalNAcalpha1-)TTGIST-NH2
UDP + Ac-PT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTGIST-NH2
-
pH 7.0, 0.2 mM, 300% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1-3GalNAcalpha1-)TTPIST-NH2
UDP + Ac-PT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTPIST-NH2
-
pH 7.0, 0.2 mM, 200% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1->3GalNAcbeta1->)TTGIST-NH2
UDP + Ac-PT-(Galbeta1->3[Glcbeta1->6]GalNAcbeta1->)TTGIST-NH2
-
pH 7.0, 0.2 mM, 95% activity
-
-
?
UDP-GlcNAc + Ac-PT-(Galbeta1->3GalNAcbeta1->)TTPIST-NH2
UDP + Ac-PT-(Galbeta1->3[GlcNAcbeta1->6]GalNAcbeta1->)TTPIST-NH2
-
pH 7.0, 0.2 mM, 185% activity
-
-
?
UDP-GlcNAc + Ac-PTT-(Galbeta1-3GalNAcalpha1-)TGIST-NH2
UDP + Ac-PTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TGIST-NH2
-
pH 7.0, 0.2 mM, 200% activity
-
-
?
UDP-GlcNAc + Ac-PTT-(Galbeta1-3GalNAcalpha1-)TPIST-NH2
UDP + Ac-PTT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPIST-NH2
-
pH 7.0, 0.2 mM, 100% activity
-
-
?
UDP-GlcNAc + Ac-PTT-(Galbeta1->3GalNAcbeta1->)TPIST-NH2
UDP + Ac-PTT-(Galbeta1->3[GlcNAcbeta1->6]GalNAcbeta1->)TPIST-NH2
-
pH 7.0, 0.2 mM, 10% activity
-
-
?
UDP-GlcNAc + AP-(Galbeta1-3GalNAcalpha1-)TSS
UDP + AP-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TSS
-
pH 7.0, 0.2 mM, 250% activity
-
-
?
UDP-GlcNAc + T-(Galbeta1-3GalNAcalpha1-)TTVTPTPTG
UDP + T-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TTVTPTPTG
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + TT-(Galbeta1-3GalNAcalpha1-)TVTPTPTG
UDP + TT-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TVTPTPTG
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + TTTV -(Galbeta1-3GalNAcalpha1-)TPTPTG
UDP + TTTV -(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPTPTG
-
pH 7.0, 0.2 mM, 75% activity
-
-
?
UDP-GlcNAc + TTTVTP-(Galbeta1-3GalNAcalpha1-)TPTG
UDP + TTTVTP-(Galbeta1-3[GlcNAcbeta1-6]GalNAcalpha1-)TPTG
-
pH 7.0, 0.2 mM, 50% activity
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosamine
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-2-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-alpha-D-galactosaminyl-2-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-beta-D-galactosaminyl-4-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-4-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + O3-[beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl]-L-seryl/threonyl-[protein]
UDP + O3-(beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl)-L-seryl/threonyl-[protein]
-
-
-
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
UDP-N-acetyl-D-glucosamine + antifreeze glycoprotein polypeptide
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-blood group A negative PSM
?
-
acceptor contains no fucose
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-(CH2)8CO2Me
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-(CH2)8CO2Me
-
synthetic disaccharide
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methylumbelliferyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methylumbelliferyl
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + D-fucosyl-beta-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + D-fucosyl-beta-1,3-(N-acetyl-D-glucosaminyl beta-1,6)-N-acetyl-alpha-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-methyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP-N-acetyl-D-glucosamine + Galbeta(1-3)GalNAcalpha-p-nitrophenol
UDP + ?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + Galbeta1-3GalNAcalpha-4-nitrophenyl
?
-
-
-
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + p-nitrophenyl 2-acetamido-2-deoxy-3-O-(beta-D-galactopyranosyl)-alpha-D-galactopyranoside
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D- galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-alpha-D-glucosamine + porcine submaxillary mucin polypeptide
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 3-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + 4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + 4-deoxy-beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-alpha1 acid glycoprotein
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-alpha1 acid glycoprotein
?
no activity
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
-
ovine asialo-submaxillary mucin
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + asialo-submaxillary mucin
?
bovine asialo-submaxillary mucin
-
-
?
UDP-N-acetyl-D-glucosamine + asialoglycophorin A
?
best substrate
-
-
?
UDP-N-acetyl-D-glucosamine + benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + benzyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
at high concentration inhibitory
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
at high concentration inhibitory
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
at high concentration inhibitory
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosamine
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosamine
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-benzyl
-
requirement for the 4- and 6-hydroxyls of N-acetyl-galactosamine and the hydroxyl of galactose in the acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-methyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-methyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-o-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-o-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
inhibitory under UV-radiation
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-phenyl
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-phenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
substrate specificity
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
substrate specificity
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
substrate specificity
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
large scale preparation
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
highly specific for both substrates
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in regulation of downstream intracellular signal transduction pathways
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in the development of cardiomyopathy
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
increased activity during E- and P-selectin ligand biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
-
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
highly specific for UDP-N-acetyl-D-glucosamine
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
i.e. core class 1, R: polypeptide
i.e. core class 2
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + fucosyl-alpha-1,2-galactosyl-beta-1,3-N-acetyl-D-galactosaminyl-R
UDP + fucosyl-alpha-1,2-galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
low activity
-
-
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + galactosyl-beta-1,3-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
UDP + galactosyl-beta-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-beta-D-glucosaminyl-p-nitrophenyl
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
-
-
-
?
UDP-N-acetyl-D-glucosamine + glycoprotein gp180
UDP + N-acetyl-beta-D-glucosaminyl-glycoprotein gp180
-
-
-
?
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
enzyme shows both core 2 beta6-GalNAc-transferase activity, EC 2.4.1.102, and core 4 beta6-GalNAc-transferase activity, EC 2.4.1.148, and is termed a type M core 2 beta6-GalNAc-transferase
i.e. core 4
?
UDP-N-acetyl-D-glucosamine + N-acetyl-beta-D-glucosaminyl-1,3-N-acetyl-alpha-D-galactosaminyl-R
UDP + N-acetyl-beta-D-glucosaminyl-1,6-(N-acetyl-beta-D-glucosaminyl-1,3)-N-acetyl-alpha-D-galactosaminyl-R
i.e. core 3
i.e. core 4
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + N-acetylgalactosaminyl-Ser(Thr)-mucin
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + phenyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + phenyl 2-acetamido-2-deoxy-alpha-D-galactopyranoside
?
-
-
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine or ovine origin of acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + submaxillary mucin polypeptide
?
-
porcine acceptor substrate
-
-
?
UDP-N-acetyl-D-glucosamine + trachea mucin
?
-
acceptor substrate is deglycosylated
-
-
?
UDP-N-acetyl-D-glucosamine + trachea mucin
?
-
porcine or human trachea mucin
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
the enzyme catalyzes the formation of all mucin beta1,6-N-acetylglucosaminides, including core 2, core 4, and blood group I structures
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
no substrates: lactose, Galbeta1-3GlcNAc, L-Fucalpha1-2Galbeta1-3GalNAc-OH, alpha- and beta-methylglycosides of galactose
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
attachment of UDPGlcNAc to serine or threonine residue
-
-
?
additional information
?
-
no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
-
-
?
additional information
?
-
no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
-
-
?
additional information
?
-
no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
-
-
?
additional information
?
-
-
no activity human transferrin and IgG, N-acetylgalactosamine, core 3 substrates
-
-
?
additional information
?
-
-
patients with Wiskott-Aldrich-Syndrome show an altered enzyme activity and inversed enzyme stimulation in T cells, enzyme activity in platelets is 3fold higher compared to normal organisms
-
-
?
additional information
?
-
-
enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
-
-
?
additional information
?
-
-
enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
-
-
?
additional information
?
-
-
M isoform is upregulated by both all-trans retinoic acid and by IL-4/13. L-isoform is moderately upregulated by IL-4/13 but not by all-trans retinoic acid
-
-
?
additional information
?
-
-
the M isoform of C2GnT can form all mucin glycan beta1,6-branched structures, including core 2, core 4, and blood group I antigen. The L-isoform forms only core 2 structures
-
-
?
additional information
?
-
-
C2GnT-1 regulates selectin ligand expression. Downregulation of the selectin ligand expression level inhibits tissue infiltration of BCP-leukemia cells
-
-
?
additional information
?
-
-
glucose levels, plasma TNF-alpha nd core 2 GlcNAc-T activity are functionally linked with dabetic retinopathy
-
-
?
additional information
?
-
-
key enzyme for the biosynthesis of sialyl-Lewis x determinants on selectin ligands
-
-
?
additional information
?
-
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
-
-
?
additional information
?
-
KRT1 binds the biotinylated CT peptide MVQWKRL of C2GnT-M isozyme
-
-
?
additional information
?
-
-
KRT1 binds the biotinylated CT peptide MVQWKRL of C2GnT-M isozyme
-
-
?
additional information
?
-
-
enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
-
-
?
additional information
?
-
-
multiple C2GlcNAcT enzymes can contribute to P-selectin ligand formation and may cooperate with C2GlcNAcT-I in the control of CD8 T cell trafficking
-
-
?
additional information
?
-
-
haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
-
-
?
additional information
?
-
the isozyme exhibits exclusive core 2 acceptor specificity. C2GnT operates through an inverting mechanism
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
-
-
?
additional information
?
-
-
no substrate: galactosyl-beta-1,3-N-acetyl-D-galactosamine
-
-
?
additional information
?
-
-
attachment of UDPGlcNAc to serine or threonine residue
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
UDP-N-acetyl-alpha-D-glucosamine + beta-D-galactosyl-(1->3)-N-acetyl-alpha-D-galactosaminyl-R
UDP + beta-D-galactosyl-(1->3)-[N-acetyl-beta-D-glucosaminyl-(1->6)]-N-acetyl-alpha-D-galactosaminyl-R
-
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in regulation of downstream intracellular signal transduction pathways
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in the development of cardiomyopathy
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
increased activity during E- and P-selectin ligand biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in biosynthesis of O-glycans core class 2
-
-
?
UDP-N-acetyl-D-glucosamine + beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-R
UDP + beta-D-galactosyl-1,3-(N-acetyl-beta-D-glucosaminyl-1,6)-N-acetyl-D-galactosaminyl-R
-
involved in mucin oligosaccharide biosynthesis
-
-
?
additional information
?
-
-
the enzyme catalyzes the formation of all mucin beta1,6-N-acetylglucosaminides, including core 2, core 4, and blood group I structures
-
-
?
additional information
?
-
-
patients with Wiskott-Aldrich-Syndrome show an altered enzyme activity and inversed enzyme stimulation in T cells, enzyme activity in platelets is 3fold higher compared to normal organisms
-
-
?
additional information
?
-
-
enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
-
-
?
additional information
?
-
-
enzyme activity is increased in patients with chronic myelogenous leukemia CML or acute myeloid leukemia AML
-
-
?
additional information
?
-
-
M isoform is upregulated by both all-trans retinoic acid and by IL-4/13. L-isoform is moderately upregulated by IL-4/13 but not by all-trans retinoic acid
-
-
?
additional information
?
-
-
C2GnT-1 regulates selectin ligand expression. Downregulation of the selectin ligand expression level inhibits tissue infiltration of BCP-leukemia cells
-
-
?
additional information
?
-
-
glucose levels, plasma TNF-alpha nd core 2 GlcNAc-T activity are functionally linked with dabetic retinopathy
-
-
?
additional information
?
-
-
key enzyme for the biosynthesis of sialyl-Lewis x determinants on selectin ligands
-
-
?
additional information
?
-
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
-
-
?
additional information
?
-
-
enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
-
-
?
additional information
?
-
-
multiple C2GlcNAcT enzymes can contribute to P-selectin ligand formation and may cooperate with C2GlcNAcT-I in the control of CD8 T cell trafficking
-
-
?
additional information
?
-
-
haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
-
-
?
additional information
?
-
-
enzyme is developmentally regulated, increased activity in hearts of diabetic organisms, regulation by hyperglycemia and insulin
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Mg2+
Mn2+
additional information
Mn2+
-
slight stimulation, 5 mM, inhibits at higher concentration
additional information
metal ion-independent enzyme. The enzyme does not contain the metal-ion-binding DXD pattern typical for inverting glycosyltransferases with the GT-A fold
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
12-O-tetradecanoylphorbol-13-acetate
-
about 10fold decreased activity, down-regulation of native enzyme in KM3 leukemia cell line, but not of the recombinant enzyme; i.e. TPA
5,5'-dithiobis-2-nitrobenzoic acid
-
inactivation is partially prevented by prior addition of donor or acceptor substrate and by sulfhydryl reducing agents. 1 mM inhibits 94%
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
and other nitrophenyl-sugar-derivatives; strong inhibition under UV-radiation at 350 nm, specific for substrate binding site, preincubation with beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl partially protects
Hydroxyphenylglyoxal
-
19% inhibition at 0.25 mM, complete inhibition at 5-10 mM
jacalin
core 1 O-glycan-specific lectin from Artocarpus integrifolia, differing sensitivity of different BoHV-4 mutants to jacalin-mediated neutralization, overview
-
NEM
-
inactivation is partially prevented by prior addition of donor or acceptor substrate and by sulfhydryl reducing agents. 0.2 mM inhibits 42%
substrate analogues lacking the 6-hydroxyl of the N-acetylgalactosamine
-
weak
-
Triton X-100
-
activation at 0.1% v/v, inhibition at higher concentrations, pig stomach
tunicamycin
-
inactivation; prevents secretion of recombinant enzyme from Sf9 cells
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
high concentration
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
high concentration
Mn2+
-
slight stimulation at 5 mM, inhibition at higher concentrations
talniflumate
selectively binds to enzyme GCNT3 via three notable hydrogen bonds between talniflumate and GCNT3. Synthesis and in silico small molecular docking simulation, overview
talniflumate
selectively binds to enzyme GCNT3 via three notable hydrogen bonds between talniflumate and GCNT3. Synthesis and in silico small molecular docking simulation, overview
UDP
-
competitive inhibition versus donor substrate, wild-type enzyme and mutant enzyme C217S
additional information
Bo17 splicing reduces BoHV-4 glycosylation
-
additional information
-
no effect of dimethyl sulfoxide, retinoic acid, phorbol ester, cholera toxin
-
additional information
-
the mutant enzyme C217S is insensitive to DTNB, iodoacetamide, NEM, HgCl2 and ZnCl2
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
sodium butyrate
-
induction after treatment of cells for 24 h, 16fold increase in activity, blocked by actinomycin D and cycloheximide
additional information
-
no effect of dimethyl sulfoxide, retinoic acid, phorbol ester, cholera toxin
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.86
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-2-nitrophenyl
-
-
-
4.2
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-methyl
-
-
-
0.92
beta-D-galactosyl-1,3-N-acetyl-beta-D-galactosaminyl-4-nitrophenyl
-
-
-
0.6
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl
-
AML cell line
3.3
3-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
AML cell line
6.7
4-deoxy-beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
AML cell line
0.52
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
-
-
-
0.92
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-4-nitrophenyl
-
-
-
0.77
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
-
-
0.8
beta-D-galactosyl-1,3-N-acetyl-alpha-D-galactosaminyl-benzyl
-
AML cell line
0.36
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
undifferentiated CaCo-2, colonic adenocarcinoma, cells
0.43
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-benzyl
-
CaCo-2, colonic adenocarcinoma, cells differentiated to enterocytes
2.8
UDP-N-acetyl-D-glucosamine
mutant enzyme C217S, in 50 mM Tris (pH 7.5), at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.95
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
AML cells
2.5
beta-D-galactosyl-1,3-(6-deoxy)-N-acetyl-D-galactosaminyl-benzyl
-
CML cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
overview: enzyme activities with several substrates
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
30
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
human Panc 1/MUC1f cells stably transfected with pcDNA3.1 containing bC2GnT-1 cDNA controlled by CMV promoter. Butyrate treatment enhances C2GnT activity in Panc 1/MUC1f-bC2GnT-1 cells in a time and butyrate concentration dependent fashion
-
-
brenda
BoHV-4, strains LVR 140, MOVAR 33/63, DN599, 66-P-347, 108, 130, and Buf representative of the BoHV-4 species isolated throughout the world and from different animal species
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
GCNT3 is elevated in skin and mesothelioma cells and in some lung and breast cancer cells
brenda
differential expression of GCNT3 gene among tumour samples from stage II colon cancer patients by quantitative reverse-transcription PCR, overview
brenda
GCNT3 gene expression is downregulated in colorectal cancer (CRC) samples in comparison to non-pathological colon tissue
brenda
-
maturation of dendritic cells leads to a rapid change in the expression of glycosyltransferases involved in O-linked glycosylation. A down-regulation of C2GnT1 mRNA and enzymatic activity is observed with a concurrent up-regulation of ST3Gal I and ST6GalNAc II mRNA resulting in a loss of the core 2 structures required for sLex expression as a P-selectin ligand
brenda
-
expression of C2GnT1 in 84 cases of endometrioid-type endometrial carcinoma, 15 cases of endometrial hyperplasia, and 30 normal endometria, immunohistochemic analysis, overview. C2GnT1 is strongly expressed at the invasive tumour front in several cases
brenda
GCNT3 expression analysis in a cohort of 56 EOC patients, followed by a meta-analysis of more than one thousand patients, overview
brenda
GCNT3 expression in Epstein-Barr virus (EBV)-associated gastric cancer cells and tissues is lower than in EBV-negative gastric cancer cells (EBVnGC) and tissues, and high expression is significantly associated with advanced tumor-lymph node metastasis. GCNT3 is closely related to the ERK signaling pathway and epithelial mesenchymal transition (EMT), regulating cell proliferation, migration, and invasion
brenda
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
brenda
GCNT3 is overexpressed in highly metastatic melanomas
brenda
GCNT3 is highly expressed in both NSCLC tissues and cell lines
brenda
-
colonic large ulcerating grade IV tumour cell line, low activity
brenda
additional information
-
acute myeloid leukemia blast cell line
brenda
-
18fold increased level compared to normal granulocytes
brenda
-
core 2 N-acetylglucosaminyltransferase is downregulated in galectin-1-resistant PSA-LNCaP cells compared with galectin-1-sensitive PSA+ LNCaP cells
brenda
-
transcription of core 2 beta1,6 N-acetylglucosaminyltransferase-I is controlled by Sp1 in lymphocytes and epithelial cells
brenda
genetically engineered Kras-driven mouse pancreatic tumors
brenda
-
genetically engineered Kras-driven mouse pancreatic tumors
-
brenda
-
core2GnT and core 2-branched O-glycans synthesized play a critical role in prostate cancer progression. Core2GnT in prostate carcinoma cells facilitates adhesion to type IV collagen and laminin, and this increased adhesion may be a cause for aggressive tumor formation by prostate cancer cells expressing core2GnT
brenda
-
GCNT1 immunohistochemic analysis, overview. The anti-GCNT1 monoclonal antibody shows high specificity against human GCNT1
brenda
-
wild-type and transgenic CD4+ T cell lines, induction by cytokines IL-4, and IL-12/STAT4
brenda
additional information
expression during virus replication cycle, MDBK cells
brenda
additional information
-
expression during virus replication cycle, MDBK cells
brenda
additional information
infection of MDBK cells with strain BoHV-4 V.test
brenda
additional information
-
production of Anti-Bo17 422-441 polyclonal monospecific antibodies from BoHV-4 V.test strain Bo17 protein and immunohistochemic analysis
brenda
additional information
-
infection of MDBK cells with strain BoHV-4 V.test
-
brenda
additional information
human pancreatic cancer tissue array consisting of 90 cases of tumor and matched normal adjacent tissue with survival data, overview
brenda
additional information
-
human pancreatic cancer tissue array consisting of 90 cases of tumor and matched normal adjacent tissue with survival data, overview
brenda
additional information
the isozyme is distributed in mucin-secreting tissues along the gastrointestinal tract
brenda
additional information
-
the isozyme is distributed in mucin-secreting tissues along the gastrointestinal tract
brenda
additional information
-
topologically, C2GnT1 is strongly expressed at sites of deep myometrial invasion
brenda
additional information
GCNT3 is highly expressed in both NSCLC tissues and cell lines, and higher expression is significantly associated with advanced tumor lymph node metastasis (TNM) stage, positive lymph node metastasis, and poor overall survival. GCNT3 expression is associated with lymph node metastasis and age. But the expression level of GCNT3 is not correlated with gender, tumor location, differentiation grade, etc.. Expression of GCNT3 is lower in EBVaGC cells and tissues than that in EBVnGC cells and tissues
brenda
additional information
-
GCNT3 is highly expressed in both NSCLC tissues and cell lines, and higher expression is significantly associated with advanced tumor lymph node metastasis (TNM) stage, positive lymph node metastasis, and poor overall survival. GCNT3 expression is associated with lymph node metastasis and age. But the expression level of GCNT3 is not correlated with gender, tumor location, differentiation grade, etc.. Expression of GCNT3 is lower in EBVaGC cells and tissues than that in EBVnGC cells and tissues
brenda
additional information
integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation. The non-invasive HT-29 cell line, that is isolated from a primary tumor, shows GCNT3 expression (mRNA and protein). By contrast, cells belonging to metastatic and invasive SW family, e.g. SW620 and SW5FU, do not exhibit measurable GCNT3 expression
brenda
additional information
-
integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation. The non-invasive HT-29 cell line, that is isolated from a primary tumor, shows GCNT3 expression (mRNA and protein). By contrast, cells belonging to metastatic and invasive SW family, e.g. SW620 and SW5FU, do not exhibit measurable GCNT3 expression
brenda
additional information
STAT4 controls Gcnt1 expression in Th1 cells, several several conserved and non-conserved predicted STAT4 binding sites are determined. Functional importance of STAT4 for P-lig induction and specifically on the enhancer as a transactivating factor. Prolonged T-bet binding to the Gcnt1 enhancer
brenda
additional information
transcriptome analysis in pacreatic carcinomas and healthy tissues
brenda
additional information
-
transcriptome analysis in pacreatic carcinomas and healthy tissues
brenda
additional information
-
transcriptome analysis in pacreatic carcinomas and healthy tissues
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
additional information
-
secretion into medium of the recombinant enzyme from Sf9 cells
-
brenda
secretion into medium of the recombinant enzyme from Sf9 cells
-
brenda
Keratin 1 retains C2GnT-M in the Golgi by interacting with its cytoplasmic tail via the rod domain
brenda
additional information
isozyme C2GnT-M targets the Golgi at the Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplasmic tail. C2GnT-M forms a complex with Giantin before KRT1, demonstrating CT-mediated sequential events of Golgi targeting and retention of C2GnT-M
-
brenda
additional information
-
isozyme C2GnT-M targets the Golgi at the Giantin site and is recycled by binding to non-muscle myosin IIA, a motor protein, via the cytoplasmic tail. C2GnT-M forms a complex with Giantin before KRT1, demonstrating CT-mediated sequential events of Golgi targeting and retention of C2GnT-M
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
malfunction
metabolism
physiological function
additional information
evolution
in contrast to cellular homologues, this virus has evolved to alternatively express two proteins from gene Bo17
evolution
-
the viral 17 gene encodes a functional homologue of the cellular Corebeta1,6GnT typeM(C2GnT-M), which was acquired from a recent ancestor of the African buffalo. Bo17 splicing is conserved among BoHV-4 strains but not in its cellular counterparts
evolution
-
in contrast to cellular homologues, this virus has evolved to alternatively express two proteins from gene Bo17
-
malfunction
C2GnT2 deficiency, impair of mucosal barrier, increase of susceptibility to colitis, reduced immunoglobulin abundance, loss of all core 4 O-glycan biosynthetic activity
malfunction
-
higher presence of the enzyme in higher stages of testicular germ cell tumors, promotes aggressive behavior of cancer cells
malfunction
-
in C2GlcNAc-TI deficient mice, decreased monocyte interactions, inhibition of monocyte recruitment, formation of small, macrophage-poor and collagen-rich atherosclerotic lesions
malfunction
a Bo17 knockout strain does not display any growth deficit in vitro. But sole expression of either of the two Bo17-encoded proteins could influence BoHV-4 growth
malfunction
aberrant GCNT3 expression is associated with increased mucin production, aggressive tumorigenesis, and reduced patient survival, and CRISPR-mediated knockout of GCNT3 in pancreatic cancer cells reduces proliferation and spheroid formation. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
malfunction
GCNT1-overexpressing cells produce a significantly larger amount of growth factors when cocultured with prostate stromal cells compared with GCNT1-knocked down cells and form larger tumors
malfunction
in mouse pancreatic cancer tumors, GCNT3 103fold upregulation is correlated with increased expression of mucins by 5-87fold. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro. CRISPR GCNT3-KO leads to reduced cell viability and spheroid formation
malfunction
loss of C2GnT-M leads to development of colitis and colon cancer. Knockdown of KRT1 by siRNA does not affect Golgi morphology but leaves C2GnT-M outside of the Golgi, resulting in the formation of sialyl-T antigen
malfunction
Gcnt1-/-Th1 cells lacking C2-GlcNAcT-I expression show impaired P-lig expression similar to Fut4+7-/-Th1 cells. In contrast to impaired P-lig expression,Gcnt1-/-and Fut4 +7-/- maintain their inflammatory competence as assessed by IFNgamma expression. Functional relevance of Gcnt1 deficiency in CD4+T cells in vivo. In line with a lack of Gcnt1 transcription, naive T cells exhibit a closed histone configuration with lowH3K4me2 and prominent H3K27me3 marks. The active H3K4me2 mark in this region increases in a time-dependent manner during Th1 differentiation
malfunction
GCNT3 overexpression reduces 5-fluorouracil resistance in colorectal cancer (CRC) cells. GCNT3 overexpression reduces proliferation, invasion and changes metabolic capacities of CRC cells. The enzyme's overexpression in epithelial ovarian cancer (EOC) patients is associated with better clinical outcome and response to initial therapy
malfunction
miR-BART1-5p directly targets GCNT3. In addition, miR-BART1-5p mimics transfection is observed to reduce cell proliferation and migration, while miR-BART1-5p inhibitor increases cell proliferation and migration following transfection. In conclusion, both miR-BART1-5p and knockdown of GCNT3 inhibit cell proliferation and migration
malfunction
silencing and functional inhibition of GCNT3 greatly suppresses migration and invasion of melanoma cells, resulting in the loss of S100A8/A9 responsiveness. siRNA-mediated GCNT3 suppression and talniflumate-mediated GCNT3 suppression significantly attenuate the basal ability of in vitro migration of WM-266-4 cells
malfunction
-
the Bo17 knockout strain does not display any growth deficit in vitro
malfunction
-
in mouse pancreatic cancer tumors, GCNT3 103fold upregulation is correlated with increased expression of mucins by 5-87fold. Inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro. CRISPR GCNT3-KO leads to reduced cell viability and spheroid formation
-
malfunction
-
a Bo17 knockout strain does not display any growth deficit in vitro. But sole expression of either of the two Bo17-encoded proteins could influence BoHV-4 growth
-
metabolism
O-glycan biosynthesis pathways and proposed O-glycan structures of selected glycosyltransferases, overview. Core 1 dominates the O-glycan repertoire. Core 1 can be further elongated by extended C1 beta3GnT3 enzyme, EC 2.4.1.146, to form extended core 1 structure, or be modified by C2 beta6GnT1 enzyme to form core 2 O-glycans. Three core 2 enzymes, C2 beta6GnT1, 2, and 3, are responsible for biosynthesis of core 2 O-glycans. C2 beta6GnT1 and 3 are almost exclusively responsible for biosynthesis of the core 2 branch, while C2 beta6GnT2 shows a significant core 4 and I-branching activity. Regulation of O-glycan biosynthesis, overview
metabolism
the enzyme is involved in the biosynthetic pathways for core2 O-glycans, overview. The core1 structure is converted to branched core2 structure (Core2) by GCNT1, GCNT3, and GCNT4
metabolism
as all fucosyltransferases 8 (FUT8), GnT-III, GnT-IV, and GnT-V use GlcNAc terminated bi-antennary glycan as acceptor substrate, the interplay among these enzymes determines the forms of glycans, e.g. the bisecting modification by GnT-III makes the glycan no longer a substrate for FUT8 and GnT-V
metabolism
integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation, response to drugs and metabolism pathways. The vascular epithelial growth factor A (VEGFA) arises as an attractive partner of GCNT3 functions in cell invasion and resistance
physiological function
Bovine herpesvirus 4 modulates its beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing. The enzyme is a homologue of the cellular core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type (C2GnT-M), which is a key player for the synthesis of complex O-glycans
physiological function
-
C2GnT1 synthesizes the core 2 branching structure by catalysing the transfer of GlcNAc from UDP-GlcNAc with a beta1,6-linkage to GalNAc of the core 1 chain. On this core 2 branch, several tumour-associated carbohydrate structures, such as sLex and sLea, are synthesized. The enzyme may be associated with the biological aggressiveness of tumour cells, relationship between the expression of C2GnT1 and clinicopathological parameters of patients with endometrial carcinoma, overview
physiological function
core 2 beta-1, 6-N-acetylglucosaminyltransferase-1 (GCNT1) is a key enzyme that forms core 2 branched O-glycans. GCNT1 expression is correlated with D'Amico's recurrence risk classification. GCNT1-negative tumors are associated with significantly better prostate-specific antigen (PSA)-free survival compared with GCNT1-positive tumors. GCNT1 expression status is an independent risk factor for PSA recurrence after radical prostatectomy
physiological function
-
enzyme GCNT1 expression in prostate cancer specimens from radical prostatectomy correlates with prostate cancer aggressiveness
physiological function
mucin-type isozyme core 2 N-acetylglucosaminyltransferase 2/M synthesizes all three beta6GlcNAc branch structures found in secreted mucins
physiological function
the isozyme shows tumour suppressor properties, together with a role of mucin production in chemotherapy sensitivity in pancreatic cancer
physiological function
the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis
physiological function
the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis. Correlation between GCNT3 expression and patient survival in human pancreatic cancer
physiological function
beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (GCNT3) is a glycosyltransferase that transfers GlcNAc to N-acetylgalactosamine (GalNAc) of the core 1 acceptor structure to form the core 2 branch in the beta-1,6 linkage. In addition to the formation of the core 2 structure, GCNT3 also functions to form the core 4 structure. GCNT3 increases MCAM stability, which enhances S100A8/A9-mediated cancer motility. Among the novel S100A8/A9 receptors, GCNT3 favorably glycosylates the MCAM receptor, extending its half-life and leading to further elevation of S100A8/A9-mediated cellular motility in melanoma cells. GCNT3 plays a pivotal role in the maintenance of MCAM protein at a high level, resulting in the acquisition of strong responsiveness to S100A8/A9 that is linked to increased cellular migration and invasion. GCNT3 expression is positively correlated to MCAM expression in patients with high-grade melanomas. GCNT3 is an upstream regulator of MCAM protein. GCNT3 plays a key role in S100A8/A9-mediated cancer motility. GCNT3 controls MCAM stability by its catalytic activity-mediated glycosyl modification that correlates with a greater ability for cancer cell motility and invasion in response to extracellular S100A8/A9
physiological function
core 2 beta1,6-N-acetylglucosaminyltransferase-I (C2GlcNAcT-I) is crucial for inflammatory homing of Th1 cells to the skin in vivo, analysis of molecular regulation of the enzyme encoded by gene Gcnt1 in CD4+T helper cells, overview. C2-GlcNAcT-I, encoded by Gcnt1, is essential for generation of P-lig and recruitment of Th1 cells into a skin-DTH reaction. Gcnt1 transcription and subsequent P-lig induction in Th1 cells is governed by binding of STAT4 and T-bet to a distal enhancer and further regulated by epigenetic marks such as H3K27me3. T-cells cultured in vitro under Th1 conditions, i.e. supplemented with IL-12, IFN gamma, and anti-IL-4, but not under Th2 (IL-4, anti-IL-12, anti-IFN gamma) or Th0 (anti-12, anti-IFNgamma and anti-IL-4) conditions, express P-lig, which corresponds to differential Gcnt1 but not Fut7 mRNA expression. STAT4 controls Gcnt1 expression in Th1 cells, several several conserved and non-conserved predicted STAT4 binding sites are determined. Functional importance of STAT4 for P-lig induction and specifically on the enhancer as a transactivating factor. Prolonged T-bet binding to the Gcnt1 enhancer
physiological function
O-glycan synthase glucosamine (N-acetyl) transferase 3 (GCNT3) is a mucin-type responsible for catalyzing core 2 and core 4 O-glycans and forming O-linked glycosylation in protein biosynthesis. Abnormal expression of GCNT3 promotes the progression of several human cancers. GCNT3 expression in Epstein-Barr virus (EBV)-associated gastric cancer cells and tissues is lower than in EBV-negative gastric cancer cells and tissues, and high expression is significantly associated with advanced tumor-lymph node metastasis. EBV may regulate GCNT3 by affecting the NF-kappaB signaling pathway. Patients with EBV-associated gastric cancer (EBVaGC) have a good survival rate. EBV potentially regulates GCNT3 by affecting the NF-kappaB signaling pathway
physiological function
-
the Bo17 gene is nonessential for virus replication, despite its contributing to posttranslational modification of virion proteins. Bo17 undergoes an alternative splicing that generates two different products of expression. In contrast to the full-length form of the protein, the shortened spliced form is devoid of enzymatic activity and confers to BoHV-4 the potential to fine-tune the core 2 branching activity of the infected cell, mechanisms to regulate the activity of glycosyltransferases from the Golgi apparatus, overview. O-Glycomic profile analysis of wild-type and mutant strains. Sole expression of either of the two Bo17-encoded proteins can influence BoHV-4 growth. Bo17 expression and splicing may affect the structure of O-glycans on BoHV-4 virions and in particular on glycoprotein gp180
physiological function
the mucin-type core 2 1,6-N-acetylglucosaminyltransferase enzyme (C2GnT-M), encoded by the GCNT3 gene, is a glycosyltransferase enzyme whose expression is altered in cancer processes. GCNT3 catalyzes the formation of core 2 O-glycan, core 4 O-glycan and I branches and its pattern of expression is mainly associated with colorectal cancer (CRC) prognosis. GCNT3 transfection in certain CRC cells reduces cell proliferation, adhesion, invasion, and induced cell death, and also inhibits tumor growth in vivo. Role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance, overview. Integrated transcriptomic and proteomic analyses reveal that GCNT3 is linked to cellular cycle, mitosis and proliferation, response to drugs and metabolism pathways. GCNT3 overexpression contributes to reduce 5-fluorouracil resistance in metastatic CRC cells. GCNT3 also diminishes cell invasion and VEGFA expression in EOC cells. GCNT3 is a cancer prognostic factor. GCNT3 diminishes cell proliferation, invasion and alters metabolic properties of CRC cells. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome
physiological function
-
the mucin-synthesizing core 2 beta-1,6 N-acetylglucosaminyltransferase (GCNT3/C2GNT) plays a significant role in mucin biosynthesis
-
physiological function
-
Bovine herpesvirus 4 modulates its beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing. The enzyme is a homologue of the cellular core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type (C2GnT-M), which is a key player for the synthesis of complex O-glycans
-
additional information
Keratin 1 retains C2GnT-M in the Golgi by interacting with its cytoplasmic tail via the rod domain. Keratin 1 plays a critical role in the regulation of O-glycosylation pathways
additional information
-
Keratin 1 retains C2GnT-M in the Golgi by interacting with its cytoplasmic tail via the rod domain. Keratin 1 plays a critical role in the regulation of O-glycosylation pathways
additional information
quantum mechanical/molecular modeling using enzyme crystal structures, PDB IDs 2GAK and 2GAM, as templates. C2GnT may occur in an open conformation, and a closed conformation. The location of the C2GnT-conserved Glu320 residue structurally corresponds to the catalytic base found in other glycosyltransferases with the GT-A fold. The enzyme-substrate system (C2GnT-UDP-GlcNAc-Galb1-3GalNAc ternary complex) consists of 379 amino acids, eight water molecules, donor, and acceptor, active site model
additional information
the two isoforms of Bo17 are expressed in BoHV-4 infected cells, but enzymatic assays revealed that the spliced form is not active
additional information
no effect of core fucosylation of substrate on the glycosyltransferase activity of GnT-III, overview
additional information
-
the splicing of the Bo17 gene gives the potential to BoHV-4 to fine-tune the global level of core 2 branching activity in the infected cell. Analysis of the structures of O-glycans isolated from cells mock infected or infected with the Bo17 Del, Bo17 MuDir, Bo17 MuDir Rev, Bo17 Spliced, and Bo17 Spliced Rev strains of BoHV-4
additional information
-
the two isoforms of Bo17 are expressed in BoHV-4 infected cells, but enzymatic assays revealed that the spliced form is not active
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). GCNT3_RAT
437
1
50642
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_SHEEP
440
1
50860
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_SYNCA
440
1
51079
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_XENLA
443
0
51202
Swiss-Prot
Secretory Pathway (Reliability: 2)
GCNT4_DANRE
428
1
49928
Swiss-Prot
Secretory Pathway (Reliability: 2)
GCNT4_HUMAN
453
1
53052
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT4_MOUSE
455
1
52832
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT1_BOVIN
427
1
49734
Swiss-Prot
Secretory Pathway (Reliability: 4)
GCNT1_HUMAN
428
1
49799
Swiss-Prot
Mitochondrion (Reliability: 5)
GCNT1_MOUSE
428
1
49839
Swiss-Prot
Mitochondrion (Reliability: 5)
GCNT3_BHV4
439
1
50741
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BHV4D
Bovine herpesvirus 4 (strain DN-599)
440
1
50764
Swiss-Prot
Secretory Pathway (Reliability: 2)
GCNT3_BHV4L
Bovine herpesvirus 4 (strain LVR140)
440
1
50720
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BHV4V
Bovine herpesvirus 4 (strain V. test)
440
1
50702
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BOSMU
440
1
50909
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BOVIN
440
1
50953
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_BUBBU
440
1
51008
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_HUMAN
438
1
50864
Swiss-Prot
Secretory Pathway (Reliability: 1)
GCNT3_MOUSE
437
1
50698
Swiss-Prot
Secretory Pathway (Reliability: 1)
A0A2H5CAB7_ELHV1
218
0
25290
TrEMBL
other Location (Reliability: 2)
A0A6J8E0X8_MYTCO
377
1
44292
TrEMBL
other Location (Reliability: 4)
A0A8B6FP45_MYTGA
409
1
48273
TrEMBL
Secretory Pathway (Reliability: 2)
A0A812DWE5_SEPPH
225
0
25643
TrEMBL
other Location (Reliability: 1)
A0A2H5CAC5_ELHV1
218
0
25218
TrEMBL
other Location (Reliability: 2)
M4JWY2_ELHV1
441
1
51404
TrEMBL
Secretory Pathway (Reliability: 1)
A0A6J8E209_MYTCO
418
0
49205
TrEMBL
Mitochondrion (Reliability: 5)
A0A6J8BCG2_MYTCO
271
0
31377
TrEMBL
other Location (Reliability: 2)
F9XAV2_ZYMTI
Zymoseptoria tritici (strain CBS 115943 / IPO323)
490
1
56649
TrEMBL
Secretory Pathway (Reliability: 1)
A0A6J8D8U9_MYTCO
156
0
18109
TrEMBL
other Location (Reliability: 4)
A0A6J8CZB6_MYTCO
435
1
50817
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8B6DBS3_MYTGA
509
1
59996
TrEMBL
Secretory Pathway (Reliability: 4)
A0A866VUR1_ELHV1
422
0
49197
TrEMBL
Secretory Pathway (Reliability: 5)
A0A2H5CAA2_ELHV1
416
0
48464
TrEMBL
other Location (Reliability: 2)
A0A866VRV4_9BETA
528
1
58552
TrEMBL
Mitochondrion (Reliability: 3)
Q801N9_XENLA
428
1
49809
TrEMBL
Secretory Pathway (Reliability: 3)
A0A812EU53_SEPPH
323
0
37866
TrEMBL
other Location (Reliability: 2)
A0A6J7ZW16_MYTCO
453
0
52917
TrEMBL
other Location (Reliability: 2)
A0A6J8DMF7_MYTCO
509
1
59894
TrEMBL
Secretory Pathway (Reliability: 5)
A0A6J8D6P1_MYTCO
353
0
41198
TrEMBL
other Location (Reliability: 3)
A0A6J8CWC1_MYTCO
389
0
45556
TrEMBL
Secretory Pathway (Reliability: 5)
A0A075CZK4_9BETA
443
1
51385
TrEMBL
Secretory Pathway (Reliability: 1)
A0A2H5CAR1_ELHV1
409
0
47629
TrEMBL
other Location (Reliability: 2)
A0A8B6EH56_MYTGA
456
0
53038
TrEMBL
other Location (Reliability: 5)
A0A8F9XNQ7_ELHV1
488
2
57022
TrEMBL
Secretory Pathway (Reliability: 3)
A0A6J8CTV4_MYTCO
391
0
46121
TrEMBL
Secretory Pathway (Reliability: 5)
A0A6J8BQ54_MYTCO
438
0
51105
TrEMBL
other Location (Reliability: 3)
A0A0S1TKJ6_9BETA
538
1
59937
TrEMBL
other Location (Reliability: 4)
A0A8B6C910_MYTGA
420
0
50081
TrEMBL
Mitochondrion (Reliability: 4)
A0A2L2FP41_ELHV1
441
1
51421
TrEMBL
Secretory Pathway (Reliability: 1)
M1RFT8_ELHV1
441
1
51404
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8B6BYD4_MYTGA
401
0
47098
TrEMBL
other Location (Reliability: 1)
A0A812DRH1_SEPPH
531
3
62014
TrEMBL
Secretory Pathway (Reliability: 5)
M4JZ77_ELHV1
441
1
51346
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8B6FRL1_MYTGA
390
0
46131
TrEMBL
other Location (Reliability: 3)
A0A8B6FRL1_MYTGA
390
0
46131
TrEMBL
other Location (Reliability: 3)
A0A2H5CAA3_ELHV1
416
0
48476
TrEMBL
other Location (Reliability: 2)
A0A866VU70_ELHV1
441
1
51404
TrEMBL
Secretory Pathway (Reliability: 1)
A0A866VTI8_ELHV1
441
1
51390
TrEMBL
Secretory Pathway (Reliability: 1)
A0A812E0M3_SEPPH
267
0
30626
TrEMBL
other Location (Reliability: 1)
A0A2H5CAA0_ELHV1
416
0
48464
TrEMBL
other Location (Reliability: 2)
A0A8B6ENQ5_MYTGA
377
0
43988
TrEMBL
other Location (Reliability: 1)
A0A8B6BV66_MYTGA
405
0
48326
TrEMBL
other Location (Reliability: 2)
A0A866VT55_ELHV1
441
1
51489
TrEMBL
Secretory Pathway (Reliability: 1)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
dimer
the monomer units of the observed dimer C2GnT possesses the GT-A fold and are connected by a disulfide bond between the Cys235 residues, quantum mechanical/molecular modeling using enzyme crystal structures, PDB IDs 2GAK and 2GAM, as templates. The structure of C2GnT contains two regions; the first (38-121) is composed of alpha-helices. The second region, which corresponds to the catalytic domain (122-428), is an alpha/beta/alpha structure consisting of a central six-stranded mixed beta-sheet. Four disulfide bonds are found in each monomer (Cys151-Cys199, Cys372-Cys381, Cys59-Cys413, and Cys100-Cys172), the remaining Cys217 is unpaired and located in the donor binding site. C2GnT may occur in an open conformation, and a closed conformation. The location of the C2GnT-conserved Glu320 residue structurally corresponds to the catalytic base found in other glycosyltransferases with the GT-A fold
monomer
additional information
-
in absence of dithiothreitol, one of the two free Cys residues (Cys217 and Cys235) is found to be engaged in an intermolecular bridge causing dimerization of the protein
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
glycoprotein
-
for C2GnT-I, the N-glycan chain linked to Asn-95 significantly contributes to the synthesis of functional P-selectin glycoprotein ligand-1 and is required to localize the enzyme to the cis/medial-Golgi compartment
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
C217S mutant in complex with UDP, hanging drop vapor diffusion method, using 24% (w/v) polyethylene glycol 4000, 0.1 M glycine (pH 9.0) and 0.6 M LiCl
hanging drop vapor diffusion method, X-ray crystal structures of murine C2GnT-L in the absence and presence of the acceptor substrate Galbeta1,3GalNAc at 2.0 and 2.7 A resolution, respectively
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
C217S
-
mutant enzyme with 41% of wild-type activity. Similar Km and Vmax values for Galbeta(1-3)GalNAcalpha-p-nitrophenol, Km-value for UDP-N-acetyl-D-glucosamine is 2.9fold higher than wild-type value. In contrast to wild-type enzyme, the mutant enzyme is not inhibited by sulfhydryl reagents and is not stimulated by reducing agents
T60A
T60A/T97A
T97A
C217S
S158C
-
mutation reduces C2GnT activity but does not affect substrate specificity or enzyme dimerization. Mutation appears to result in haploinsufficiency of C2GnT activity. C2GnT-I haploinsufficiency is sufficient for loss of core 2 O-glycan expression and galectin-1 resistance
additional information
T60A
-
about 65% of the wild-type in vitro activity, mutation results in a significant increase in electrophoretic mobilities of the protein
T60A/T97A
-
about 6% of the wild-type in vitro activity, mutant loses the ability of branching P-selectin glycoprotein ligand-1 O-glycans
T97A
-
about 25% of the wild-type in vitro activity, mutation results in a significant increase in electrophoretic mobilities of the protein
C217S
-
Cys217 although not required for activity per se, represents the only thiol that causes enzyme inactivation when modified. KM-value for UDP-N-acetyl-D-glucosamine is about 5% higher than the wild-type value, the Km-value for Galbeta(1-3)GalNAcalpha-p-nitrophenol is about 20% higher than the wild-type value.Unlike the wild-type enzyme the mutant enzyme can be stored at 4°C for at least 3 months without any loss of activity. The mutant enzyme is insensitive to DTNB, iodoacetamide, NEM, HgCl2 and ZnCl2
additional information
-
production of BoHV-4 Bo17 mutant strains, i.e. the BoHV-4 V.test strain deleted for the Bo17 ORF (Bo17 Del) and the corresponding revertant strain (Bo17 Rev). The recombinant strains Bo17 MuDir and Bo17 Spliced are derived from a cloned BoHV-4 bacterial artificial chromosome (BAC). The Bo17 MuDir sequence is generated by site-directed mutagenesis, two mutations are inserted in the 5' splice site and one mutation in the 3' splice site. O-Glycomic profile analysis of wild-type and mutant strains. The Bo17 knockout strain does not display any growth deficit in vitro. Analysis of the structures of O-glycans isolated from cells mock infected or infected with the Bo17 Del, Bo17 MuDir, Bo17 MuDir Rev, Bo17 Spliced, and Bo17 Spliced Rev strains of BoHV-4. The infection by wild-type, Bo17 MuDir, and the revertant strains is moderately inhibited by jacalin, this neutralization is significantly stronger for the Bo17 Del strain and even more for the Bo17 Spliced strain
additional information
construction of a catalytic dead GCNT3 (mutGCNT3) cDNA designed for expression as C-terminally 3xMyc-6His-tagged deletion form (lacking the region from 323 aa through 438 aa). siRNA-mediated GCNT3 suppression in WM-266-4 cells. Forced expression of mutGCNT3 significantly downregulates migration activity of WM-266-4 cells under either the presence or absence of S100A8/A9 in culture
additional information
-
construction of a catalytic dead GCNT3 (mutGCNT3) cDNA designed for expression as C-terminally 3xMyc-6His-tagged deletion form (lacking the region from 323 aa through 438 aa). siRNA-mediated GCNT3 suppression in WM-266-4 cells. Forced expression of mutGCNT3 significantly downregulates migration activity of WM-266-4 cells under either the presence or absence of S100A8/A9 in culture
additional information
GCNT3 downregulation by shGCNT3 7. GCNT3 overexpression reduces 5-fluorouracil resistance in colorectal cancer (CRC) cells. GCNT3 overexpression reduces proliferation, invasion and changes metabolic capacities of CRC cells. Genomic analysis of GCNT3 overexpression, overview
additional information
-
GCNT3 downregulation by shGCNT3 7. GCNT3 overexpression reduces 5-fluorouracil resistance in colorectal cancer (CRC) cells. GCNT3 overexpression reduces proliferation, invasion and changes metabolic capacities of CRC cells. Genomic analysis of GCNT3 overexpression, overview
additional information
knockdown of GCNT3 using GCNT3-specific small interfering RNAs: siGCNT3-1 (GCUACUGCGAGCUGUGUAUTT), and siGCNT3-2 (GCUCAGUGCCGUGGAAAUATT). Reduction of the expression of endogenous GCNT3 by siRNA transfection in SGC7901 and BGC823 cells. Epstein-Barr virus (EBV) miRNA miR-BART1-5p specifically targets GCNT3. miR-BART1-5p suppresses GCNT3 expression, cell proliferation, and migration in EBVnGC, and the MiR-BART1-5p inhibitor increases GCNT3 expression, cell proliferation, and migration in transfected GT39 and GT38 cells. NF-kappaB can activate the expression of multiple miR-BARTs, including miR-BART1-5p
additional information
-
knockdown of GCNT3 using GCNT3-specific small interfering RNAs: siGCNT3-1 (GCUACUGCGAGCUGUGUAUTT), and siGCNT3-2 (GCUCAGUGCCGUGGAAAUATT). Reduction of the expression of endogenous GCNT3 by siRNA transfection in SGC7901 and BGC823 cells. Epstein-Barr virus (EBV) miRNA miR-BART1-5p specifically targets GCNT3. miR-BART1-5p suppresses GCNT3 expression, cell proliferation, and migration in EBVnGC, and the MiR-BART1-5p inhibitor increases GCNT3 expression, cell proliferation, and migration in transfected GT39 and GT38 cells. NF-kappaB can activate the expression of multiple miR-BARTs, including miR-BART1-5p
additional information
-
construction of transgenic mice by microinjection of rat cDNA fused to a rat cardiac-specific promotor into pronuclei of fertilized FVB mouse eggs, overexpression and increase of enzyme activity in the heart leading to cardiac hypertrophy, elevated content of sialylated O-glycans, induction of c-fos expression, and phenotypic changes
additional information
-
fusion protein of major histocompatibility complex class II chaperone invariant chain and C2GnT, immunization with this construct leads to reduced growth of Panc02 pancreatic tumor cells
additional information
p48Cre/+-LSL-KrasG12D+þ GEM with Kras mutations display significant dysregulation of EGF receptor and upregulation of mucin biosynthesis in PanIN lesions and pancreatic ductal adenocarcinoma, genotyping
additional information
-
p48Cre/+-LSL-KrasG12D+þ GEM with Kras mutations display significant dysregulation of EGF receptor and upregulation of mucin biosynthesis in PanIN lesions and pancreatic ductal adenocarcinoma, genotyping
additional information
-
p48Cre/+-LSL-KrasG12D+þ GEM with Kras mutations display significant dysregulation of EGF receptor and upregulation of mucin biosynthesis in PanIN lesions and pancreatic ductal adenocarcinoma, genotyping
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
37
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
freeze-drying and resuspension in 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 95% remaining activity
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
OXIDATION STABILITY
ORGANISM
UNIPROT
LITERATURE
inactivation during storage may be caused by air oxidation and points to a requirement for inmodified thiols in the core protein
-
659276
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
mutant enzyme C217S can be stored at 4°C for at least 3 months without any loss of activity, wild-type enzyme loses about 95% of its activity after 4 weeks
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
-70C, microsomal preparation, detergent-free 0.25 M sucrose suspension, several years
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
CHO cells stably transfected with a pSEcTag plasmid, This plasmid contains bC2GnT-M cDNA devoid of the 5'-sequence coding the cytoplasmic tail and transmembrane domain
-
cloning and expression of isozyme 3 in Spodoptera frugiperda Sf9 insect cells via baculovirus infection, secretion of the enzyme
coexpression of isozyme 3 with leukosialin as substrate in CHO cells for in vivo activity assay of the enzyme
cotransfection and expression of Epstein-Barr virus (EBV) miRNA miR-BART1-5p and GCNT3 in HEK-293T and SGC7901 cells
expression in human pancreatic cancer cell line Panc1-MUC1, which lacks enzyme C2GnT activity, alters the expression of MUC1-epitope in the same cell line
-
expression in Spodoptera frugiperda Sf9 insect cells via baculovirus infection, truncated enzyme form
-
functional expression in CHO cells, direction of enzyme activity onto the cell surface, a soluble chimeric enzyme form shows also core 4 6beta-GalNAc transferase activity, DNA and amino acid sequence determination
gene Bo17, DNA and amino acid sequence determination and analysis, two different mRNAs are encoded by the Bo17 gene of all available BoHV-4 strains. While the first one corresponds to the entire coding sequence of the Bo17 gene, the second results from the splicing of a 138-bp intron encoding critical residues of the enzyme. The first one is enzymatically active, the second is inactive and results from the alternative splicing of the region encoding the catalytic site of the enzyme, enzyme activities in infected cells, overview
gene GCNT1 , recombinant expression in CHO-K1 cells. Glycosylation-related genes in CHO-K1 cells are present, but strictly suppressed and regulated. CHO cells are transiently co-transfected with plasmids encoding extended C1 beta3GnT3, C2 beta6GnT1, or C3 beta3GnT6 with or without ST6Gal I or CHST4, respectively, and resulting O-glycan and core chain spectrum, overview
gene Gcnt1, identification of the Gcnt1 promoter, identification of a putative distal regulatory element of the Gcnt1 gene by mapping H3K4me2 and H3K27me3 across the Gcnt1 locus, sequence comparisons, phylogenetic analysis of promoters, overview. The distal regulatory region is an enhancer forGcnt1 for which STAT4 is functionally important. Prolonged T-bet binding to the Gcnt1 enhancer
gene GCNT3 expression analysis in pancreatic cancer and in healthy pancreatic tissue, gene expression profiling and transcriptome analysis
gene GCNT3, quantitative reverse-transcription PCR enzyme expression analysis
gene GCNT3, recombinant expression of C-terminally 3xMyc-6His-tagged wild-type enzyme and deletion mutant mutGCNT3
gene GCNT3, recombinant overexpression in SW620 and SW5FU cell lines, genomic analysis of GCNT3 overexpression, quantitative RT-PCR enzyme expression analysis, genomic and proteomic landscapes of GCNT3 are linked to cell cycle and response to drug pathways. GCNT3 overexpression does not significantly change cell growth in Caov3 cells, VEGFA expression is downregulated in GCNT3 Caov3 cells
HH and BW5147 cells are transfected with either wild-type or mutant human C2GnT-I cDNA. Expression of C2GnT-I makes HH cells susceptible to galectin-1
-
recombinant expression of C-terminally c-Myc-tagged betaC2GnT-M in Panc1 cells, transient expression of GFP-tagged C2GnT-M in HeLa cells. Yeast two-hybrid analysis of the interactions between KRT1 protein head, tail, or rod domain and the cytoplasmic peptides of hC2GnT-M
the Bo17 gene of Bovine herpesvirus 4 (BoHV-4) encodes a homologue of the cellular core 2 protein beta-1,6-N-acetylglucosaminyltransferase-mucin type (C2GnT-M), which is a key player for the synthesis of complex O-glycans. As opposed to what is observed for the cellular enzyme, two different mRNAs are encoded by the Bo17 gene of all available BoHV-4 strains. Bo17 undergoes an alternative splicing that generates two different products of expression. While the first one corresponds to the entire coding sequence of the Bo17 gene, the second results from the splicing of a 138-bp intron encoding critical residues of the enzyme. The two forms of Bo17 are expressed in BoHV-4 infected cells, but the spliced form is not active, recombinant expression of only the long or the short form of Bo17, RT-PCR expression analysis
-
the recombinant protein generated by mC2GnT-M cDNA exhibits core 2, core 4, and blood group I enzyme activities with a ratio of 1.00:0.46:1.05
gene GCNT3 expression analysis in pancreatic cancer and in healthy pancreatic tissue, gene expression profiling and transcriptome analysis
gene GCNT3 expression analysis in pancreatic cancer and in healthy pancreatic tissue, gene expression profiling and transcriptome analysis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
activation-induced enzyme up-regulation under permissive (T helper type 1) conditions is strongly reduced by cyclosporin A
-
GCNT3 downregulation by shGCNT3 7, of several shRNAs targeting GCNT3 shGCNT3s, shGCNT3 7 has the best inhibitory capacity (protein and mRNA)
inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
modulation of GCNT3 expression in the presence of 5-fluorouracil (5FU) at 0.03 mM, a robust induction of GCNT3 expression is observed in SW family of non-resistant cells with a statistically significant 3.76fold increase in SW620 metastatic cells, while no such induction is observed in SW5FU cells or in HT-29 cell line, which has the highest levels of endogenous GCNT3
STAT4 controls Gcnt1 expression in Th1 cells, several conserved and non-conserved predicted STAT4 binding sites are determined
the three chemotherapeutic agents, with different mechanism of action, 5-fluorouracil, bortezomib and paclitaxel significantly induce GCNT3 expression in several cancer cells, but not in drug-unreponsive cells
inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
inhibitor talniflumate alone and in combination with low-dose gefitinib reduced GCNT3 expression, leading to the disrupted production of mucins in vivo and in vitro
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
diagnostics
medicine
molecular biology
-
beta-D-galactosyl-1,3-N-acetyl-D-galactosaminyl-p-nitrophenyl and other nitrophenyl-sugar-derivatives are useful as specific inhibitors and as affinity label
synthesis
-
chemical-enzymatic synthesis of sialyl-Lex-containing hexasaccharides found on O-linked glycoproteins, process involves several enzymes of the pathway
diagnostics
-
C2GnT1 might become a prognostic factor for endometrial carcinoma. Patients with C2GnT1 overexpression show significantly shorter survival, multivariable analysis also indicate that 2GnT1 overexpression is an independent prognostic factor
diagnostics
-
detection of core2 beta-1,6-N-acetylglucosaminyltransferase in post-digital rectal examination urine is a reliable indicator for extracapsular extension of prostate cancer. The number of GCNT1-positive cases is significantly lower in cases of organ-confined disease than in cases of extracapsular extension. GCNT1-negative tumors are a associated with significantly better prostate-specific antigen (PSA)-free survival compared with GCNT1-positive tumors. Multivariate analysis reveals that detection of GCNT1 expression is an independent risk factor for prostate-specific antigen recurrence
diagnostics
GCNT1 expression in prostate biopsy specimen is a significant and independent predictor of recurrence after radical prostatectomy, which can be used in pre-treatment decision making for the patient
diagnostics
possible role of GCNT3 gene expression as prognostic marker in colon cancer. Low CNT3 expression is a promising prognostic biomarker for colon cancer that could be used to identify early-stage colon cancer patients at high risk of relapse. The enzyme might also constitute a biomarker to monitor tumour response to chemotherapy in cancer patients
diagnostics
GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview
medicine
-
C2GnT-1 may be a candidate of therapeutic target for the inhibition of infiltration of leukemia cells
medicine
-
core2GnT is an extremely useful prognostic marker for prostate cancer progression
medicine
-
good drug targets for the treatment of inflammatory disorders and other pathologies involving selectins
medicine
-
the results reveal a rationale towards a specific treatment of diabetic retinopathy, based on the inhibition of core 2 GlcNAc-T activity and/or the blockage of cognate glycans
medicine
clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer, clinicopathological parameters, overview
medicine
GCNT1 expression in prostate biopsy specimen is a significant and independent predictor of recurrence after radical prostatectomy, which can be used in pre-treatment decision making for the patient
medicine
GCNT3 is a potential molecular target in melanoma therapeutics through abrogation of the S100A8/A9-MCAM axis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Schachter, H.; Brockhausen, I.; Hull, E.
High-performance liquid chromatography assays for N-acetylglucosaminyltransferases involved in N- and O-glycan synthesis
Methods Enzymol.
179
351-397
1989
Bos taurus, Canis lupus familiaris, Oryctolagus cuniculus, Ovis aries, Homo sapiens, Platyrrhini, Rattus norvegicus, Sus scrofa
brenda
Mendicino, J.; Sangadala, S.
Purification and characterization of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase from swine trachea epithelium
Mol. Cell. Biochem.
185
135-145
1998
Sus scrofa
brenda
Oehrlein, R.; Hindsgaul, O.; Palcic, M.M.
Use of the core-2-N-acetylglucosaminyltransferase in the chemical-enzymic synthesis of a sialyl-LeX-containing hexasaccharide found on O-linked glycoproteins
Carbohydr. Res.
244
149-159
1993
Mus musculus
brenda
Higgins, E.A.; Siminovitch, K.A.; Zhuang, D.; Brockhausen, I.; Dennis, J.W.
Aberrant O-linked oligosaccharide biosynthesis in lymphocytes and platelets from patients with the Wiskott-Aldrich syndrome
J. Biol. Chem.
266
6280-6290
1991
Homo sapiens
brenda
Kuhns, W.; Rutz, V.; Paulsen, H.; Matta, K.L.; Baker, M.A.; Barner, M.; Granovsky, M.; Brockhausen, I.
Processing O-glycan core 1, Galb1-3GalNAca-R. Specificities of core 2, UDP-GlcNAc: Galbeta1-3GalNAc-R(GlcNAc to GalNAc) beta6-N-acetylglucosaminyltransferase and CMP-sialic acid: Galbeta1-3GalNAc-R alpha3-sialyltransferase
Glycoconjugate J.
10
381-394
1993
Gallus gallus, Homo sapiens, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Brockhausen, I.; Rachaman, E.S.; Matta, K.L.; Schachter, H.
The separation by liquid chromatography (under elevated pressure) of phenyl, benzyl, and O-nitrophenyl glycosides of oligosaccharides. Analysis of substrates and products for four N-acetyl-D-glucosaminyl-transferases involved in mucin synthesis
Carbohydr. Res.
120
3-16
1983
Canis lupus familiaris, Rattus norvegicus, Sus scrofa
brenda
Brockhausen, I.; Matta, K.L.; Orr, J.; Schachter, H.
Mucin synthesis. UDP-GlcNAc:GalNAc-R beta 3-N-acetylglucosaminyltransferase and UDP-GlcNAc:GlcNAc beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from pig and rat colon mucosa
Biochemistry
24
1866-1874
1985
Canis lupus familiaris, Rattus norvegicus, Sus scrofa
brenda
Vavasseur, F.; Yang, J.M.; Dole, K.; Paulsen, H.; Brockhausen, I.
Synthesis of O-glycan core 3: characterization of UDP-GlcNAc:GalNAc-R beta3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines
Glycobiology
5
351-357
1995
Homo sapiens
brenda
Williams, D.; Schachter, H.
Mucin synthesis. I. Detection in canine submaxillary glands of an N-acetylglucosaminyltransferase which acts on mucin substrates
J. Biol. Chem.
255
11247-11252
1980
Canis lupus familiaris
brenda
Williams, D.; Longmore, G.; Matta, K.L.; Schachter, H.
Mucin synthesis. II. Substrate specificity and product identification studies on canine submaxillary gland UDP-GlcNAc:Gal beta 1-3GalNAc(GlcNAc leads to GalNAc) beta 6-N-acetylglucosaminyltransferase
J. Biol. Chem.
255
11253-11261
1980
Canis lupus familiaris
brenda
Datti, A.; Dennis, J.W.
Regulation of UDP-GlcNAc:Galbeta1-3GalNAc-R beta1-6-N-acetylglucosaminyltransferase (GlcNAc to GalNAc) in chinese hamster ovary cells
J. Biol. Chem.
268
5409-5416
1993
Cricetulus griseus
brenda
Toki, D.; Granovsky, M.A.; Reck, F.; Kuhns, W.; Baker, M.A.; Matta, K.L.; Brockhausen, I.
Inhibition of UDP-GlcNAc:Gal beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from acute myeloid leukaemia cells by photoreactive nitrophenyl substrate derivatives
Biochem. Biophys. Res. Commun.
198
417-423
1994
Homo sapiens, Rattus norvegicus, Sus scrofa
brenda
Zeng, S.; Dinter, A.; Eisenkratzer, D.; Biselli, M.; Wandrey, C.; Berger, E.G.
Pilot scale expression and purification of soluble protein A tagged beta1,6N-acetylglucosaminyltransferase in CHO cells
Biochem. Biophys. Res. Commun.
237
653-658
1997
Mus musculus
brenda
Toki, D.; Sarkar, M.; Yip, B.; Reck, F.; Joziasse, D.; Fukuda, M.; Schachter, H.; Brockhausen, I.
Expression of stable human O-glycan core 2 beta-1,6-N-acetylglycosaminyltransferase in Sf9 insect cells
Biochem. J.
325
63-69
1997
Homo sapiens
-
brenda
Nakamura, M.; Kudo, T.; Narimatsu, H.; Furukawa, Y.; Kikuchi, J.; Asakura, S.; Yang, W.; Iwase, S.; Hatake, K.; Miura, Y.
Single glycosyltransferase, core 2 beta1-6-N-acetylglucosaminyltransferase, regulates cell surface sialyl-Lex expression level in human pre-B lymphocytic leukemia cell line KM3 treated with phorbolester
J. Biol. Chem.
273
26779-26789
1998
Homo sapiens
brenda
Beum, P.V.; Singh, J.; Burdick, M.; Hollingsworth, M.A.; Cheng, P.W.
Expression of core 2 beta-1,6-N-acetylglucosaminyltransferase in a human pancreatic cancer cell line results in altered expression of MUC1 tumor-associated epitopes
J. Biol. Chem.
274
24641-24648
1999
Homo sapiens
brenda
Schwientek, T.; Yeh, J.C.; Levery, S.B.; Keck, B.; Merkx, G.; Van Kessel, A.G.; Fukuda, M.; Clausen, H.
Control of O-glycan branch formation: molecular cloning and characterization of a novel thymus-associated core 2 beta1,6-N-acetylglucosaminyltransferase
J. Biol. Chem.
275
11106-11113
2000
Homo sapiens (O95395), Homo sapiens (Q02742), Homo sapiens (Q9P109), Homo sapiens
brenda
Koya, D.; Dennis, J.W.; Warren, C.E.; Takahara, N.; Schoen, F.J.; Nishio, Y.; Nakajima, T.; Lipes, M.A.; King, G.L.
Overexpression of core 2 N-acetylglycosaminyltransferase enhances cytokine actions and induces hypertrophic myocardium in transgenic mice
FASEB J.
13
2329-2337
1999
Mus musculus, Rattus norvegicus
brenda
Vanderplasschen, A.; Markine-Goriaynoff, N.; Lomonte, P.; Suzuki, M.; Hiraoka, N.; Yeh, J.C.; Bureau, F.; Willems, L.; Thiry, E.; Fukuda, M.; Pastoret, P.P.
A multipotential beta-1,6-N-acetylglucosaminyltransferase is encoded by bovine herpesvirus type 4
Proc. Natl. Acad. Sci. USA
97
5756-5761
2000
Bovine gammaherpesvirus 4 (Q9IZK2), Bovine gammaherpesvirus 4
brenda
Lim, Y.C.; Xie, H.; Come, C.E.; Alexander, S.I.; Grusby, M.J.; Lichtman, A.H.; Luscinskas, F.W.
IL-12, STAT4-dependent up-regulation of CD4+ T cell core 2 beta-1,6-n-acetylglucosaminyltransferase, an enzyme essential for biosynthesis of P-selectin ligands
J. Immunol.
167
4476-4484
2001
Mus musculus
brenda
Brockhausen, I.; Kuhns, W.; Schachter, H.; Matta K.L.; Sutherland, D.R.; Baker, M.A.
Biosynthesis of O-glycans in leukocytes from normal donors and from patients with leukemia: increase in O-glycan core 2 UDP-GlcNAc:Galbeta3GalNAcalpha-R (GlcNAc to GalNAc) beta(1,6)-N-acetylglucosaminyltransferase in leikemic cells
Cancer Res.
51
1257-1263
1991
Homo sapiens
brenda
Brockhausen, I.; Romero, P.A.; Herscovics, A.
Glycosyltransferase changes upon differentiation of CaCo-2 human colonic adenocarcinoma cells
Cancer Res.
51
3136-3142
1991
Homo sapiens
brenda
Beum, P.V.; Basma, H.; Bastola, D.R.; Cheng, P.W.
Mucin biosynthesis: upregulation of core 2 beta 1,6 N-acetylglucosaminyltransferase by retinoic acid and Th2 cytokines in a human airway epithelial cell line
Am. J. Physiol.
288
L116-124
2005
Homo sapiens
brenda
Yang, X.; Qin, W.; Lehotay, M.; Toki, D.; Dennis, P.; Schutzbach, J.S.; Brockhausen, I.
Soluble human core 2 beta6-N-acetylglucosaminyltransferase C2GnT1 requires its conserved cysteine residues for full activity
Biochim. Biophys. Acta
1648
62-74
2003
Homo sapiens
brenda
Yen, T.Y.; Macher, B.A.; Bryson, S.; Chang, X.; Tvaroska, I.; Tse, R.; Takeshita, S.; Lew, A.M.; Datti, A.
Highly conserved cysteines of mouse core 2 beta1,6-N-acetylglucosaminyltransferase I form a network of disulfide bonds and include a thiol that affects enzyme activity
J. Biol. Chem.
278
45864-45881
2003
Mus musculus
brenda
Singh, J.; Khan, G.A.; Kinarsky, L.; Cheng, H.; Wilken, J.; Choi, K.H.; Bedows, E.; Sherman, S.; Cheng, P.W.
Identification of disulfide bonds among the nine core 2 N-acetylglucosaminyltransferase-M cysteines conserved in the mucin beta6-N-acetylglucosaminyltransferase family
J. Biol. Chem.
279
38969-38977
2004
Bos taurus
brenda
Merzaban, J.S.; Zuccolo, J.; Corbel, S.Y.; Williams, M.J.; Ziltener, H.J.
An alternate core 2 beta1,6-N-acetylglucosaminyltransferase selectively contributes to P-selectin ligand formation in activated CD8 T cells
J. Immunol.
174
4051-4059
2005
Mus musculus
brenda
Prorok-Hamon, M.; Notel, F.; Mathieu, S.; Langlet, C.; Fukuda, M.; El-Battari, A.
N-glycans of core2 beta(1,6)-N-acetylglucosaminyltransferase-I (C2GnT-I) but not those of alpha(1,3)-fucosyltransferase-VII (FucT-VII) are required for the synthesis of functional P-selectin glycoprotein ligand-1 (PSGL-1): effects on P-, L- and E-selectin
Biochem. J.
391
491-502
2005
Homo sapiens
brenda
Cabrera, P.V.; Amano, M.; Mitoma, J.; Chan, J.; Said, J.; Fukuda, M.; Baum, L.G.
Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
Blood
108
2399-2406
2006
Mus musculus
brenda
Ben-Mahmud, B.M.; Chan, W.H.; Abdulahad, R.M.; Datti, A.; Orlacchio, A.; Kohner, E.M.; Chibber, R.
Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy
Diabetologia
49
2185-2191
2006
Homo sapiens
brenda
Hagisawa, S.; Ohyama, C.; Takahashi, T.; Endoh, M.; Moriya, T.; Nakayama, J.; Arai, Y.; Fukuda, M.
Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression
Glycobiology
15
1016-1024
2005
Homo sapiens
brenda
Falkenberg, V.R.; Fregien, N.
Control of core 2 beta1,6 N-acetylglucosaminyltransferase-I transcription by Sp1 in lymphocytes and epithelial cells
Glycoconj. J.
24
511-519
2007
Homo sapiens
brenda
Pak, J.E.; Arnoux, P.; Zhou, S.; Sivarajah, P.; Satkunarajah, M.; Xing, X.; Rini, J.M.
X-ray crystal structure of leukocyte type core 2 beta1,6-N-acetylglucosaminyltransferase. Evidence for a convergence of metal ion-independent glycosyltransferase mechanism
J. Biol. Chem.
281
26693-26701
2006
Mus musculus
brenda
Kikuchi, J.; Ozaki, H.; Nonomura, C.; Shinohara, H.; Iguchi, S.; Nojiri, H.; Hamada, H.; Kiuchi, A.; Nakamura, M.
Transfection of antisense core 2 beta1,6-N-acetylglucosaminyltransferase-1 cDNA suppresses selectin ligand expression and tissue infiltration of B-cell precursor leukemia cells
Leukemia
19
1934-1940
2005
Homo sapiens
brenda
Radhakrishnan, P.; Beum, P.V.; Tan, S.; Cheng, P.W.
Butyrate induces sLex synthesis by stimulation of selective glycosyltransferase genes
Biochem. Biophys. Res. Commun.
359
457-462
2007
Bos taurus
brenda
Valenzuela, H.F.; Pace, K.E.; Cabrera, P.V.; White, R.; Porvari, K.; Kaija, H.; Vihko, P.; Baum, L.G.
O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1
Cancer Res.
67
6155-6162
2007
Homo sapiens
brenda
Hashimoto, M.; Tan, S.; Mori, N.; Cheng, H.; Cheng, P.W.
Mucin biosynthesis: molecular cloning and expression of mouse mucus-type core 2 beta1,6 N-acetylglucosaminyltransferase
Glycobiology
17
994-1006
2007
Mus musculus (Q5JCT0), Mus musculus
brenda
Julien, S.; Grimshaw, M.J.; Sutton-Smith, M.; Coleman, J.; Morris, H.R.; Dell, A.; Taylor-Papadimitriou, J.; Burchell, J.M.
Sialyl-Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: a mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I
J. Immunol.
179
5701-5710
2007
Homo sapiens
brenda
Wang, H.; Tang, R.; Zhang, W.; Amirikian, K.; Geng, Z.; Geng, J.; Hebbel, R.P.; Xia, L.; Marth, J.D.; Fukuda, M.; Katoh, S.; Huo, Y.
Core2 1-6-N-glucosaminyltransferase-I is crucial for the formation of atherosclerotic lesions in apolipoprotein E-deficient mice
Arterioscler. Thromb. Vasc. Biol.
29
180-187
2009
Mus musculus
brenda
Brockhausen, I.; Dowler, T.; Paulsen, H.
Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2
Biochim. Biophys. Acta
1790
1244-1257
2009
Homo sapiens
brenda
Hatakeyama, S.; Kyan, A.; Yamamoto, H.; Okamoto, A.; Sugiyama, N.; Suzuki, Y.; Yoneyama, T.; Hashimoto, Y.; Koie, T.; Yamada, S.; Saito, H.; Arai, Y.; Fukuda, M.; Ohyama, C.
Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor
Int. J. Cancer
127
10521-10529
2010
Homo sapiens
brenda
Wang, J.; Shiratori, I.; Satoh, T.; Lanier, L.L.; Arase, H.
An essential role of sialylated O-linked sugar chains in the recognition of mouse CD99 by paired Ig-like type 2 receptor (PILR)
J. Immunol.
180
1686-1693
2008
Mus musculus (Q09324), Mus musculus
brenda
Stone, E.L.; Ismail, M.N.; Lee, S.H.; Luu, Y.; Ramirez, K.; Haslam, S.M.; Ho, S.B.; Dell, A.; Fukuda, M.; Marth, J.D.
Glycosyltransferase function in core 2-type protein O glycosylation
Mol. Cell. Biol.
29
3770-3782
2009
Mus musculus, Mus musculus (Q5JCT0)
brenda
Nagaraj, S.; Neumann, J.; Winzen, B.; Frank, S.; Ziske, C.; Sievers, E.; Koch, N.; Schmidt-Wolf, I.G.
Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition
Pancreas
37
321-327
2008
Mus musculus
brenda
Schroeter, M.F.; Ratsch, B.A.; Lehmann, J.; Baumgrass, R.; Hamann, A.; Syrbe, U.
Differential regulation and impact of fucosyltransferase VII and core 2 beta1,6-N-acetyl-glycosaminyltransferase for generation of E- and P-selectin ligands in murine CD4+ T cells
Immunology
137
294-304
2012
Mus musculus
brenda
Pak, J.E.; Satkunarajah, M.; Seetharaman, J.; Rini, J.M.
Structural and mechanistic characterization of leukocyte-type core 2 ?1,6-N-acetylglucosaminyltransferase: a metal-ion-independent GT-A glycosyltransferase
J. Mol. Biol.
414
798-811
2011
Mus musculus (Q09324)
brenda
Sato, T.; Yoneyama, T.; Tobisawa, Y.; Hatakeyama, S.; Yamamoto, H.; Kojima, Y.; Mikami, J.; Mori, K.; Hashimoto, Y.; Koie, T.; Ohyama, C.
Core 2 beta-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness
Biochem. Biophys. Res. Commun.
470
150-156
2016
Homo sapiens (Q02742), Homo sapiens
brenda
Rao, C.; Janakiram, N.; Madka, V.; Kumar, G.; Scott, E.; Pathuri, G.; Bryant, T.; Kutche, H.; Zhang, Y.; Biddick, L.; Gali, H.; Zhao, Y.; Lightfoot, S.; Mohammed, A.
Small-molecule inhibition of GCNT3 disrupts mucin biosynthesis and malignant cellular behaviors in pancreatic cancer
Cancer Res.
76
1965-1974
2016
Homo sapiens (O95395), Homo sapiens, Mus musculus (Q5JCT0), Mus musculus, Mus musculus C57BL/6 (Q5JCT0)
brenda
Tvaroska, I.; Kozmon, S.; Wimmerova, M.; Koca, J.
A QM/MM investigation of the catalytic mechanism of metal-ion-independent core 2 beta1,6-N-acetylglucosaminyltransferase
Chemistry
19
8153-8162
2013
Mus musculus (Q09324)
brenda
Gonzalez-Vallinas, M.; Vargas, T.; Moreno-Rubio, J.; Molina, S.; Herranz, J.; Cejas, P.; Burgos, E.; Aguayo, C.; Custodio, A.; Reglero, G.; Feliu, J.; Ramirez de Molina, A.
Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer
Eur. J. Cancer
51
1-8
2015
Homo sapiens (O95395), Homo sapiens
brenda
Miyamoto, T.; Suzuki, A.; Asaka, R.; Ishikawa, K.; Yamada, Y.; Kobara, H.; Nakayama, J.; Shiozawa, T.
Immunohistochemical expression of core 2 beta1,6-N-acetylglucosaminyl transferase 1 (C2GnT1) in endometrioid-type endometrial carcinoma: a novel potential prognostic factor
Histopathology
62
986-993
2013
Homo sapiens
brenda
Petrosyan, A.; Ali, M.F.; Cheng, P.W.
Keratin 1 plays a critical role in Golgi localization of core 2 N-acetylglucosaminyltransferase M via interaction with its cytoplasmic tail
J. Biol. Chem.
290
6256-6269
2015
Homo sapiens (O95395), Homo sapiens
brenda
Liu, J.; Jin, C.; Cherian, R.M.; Karlsson, N.G.; Holgersson, J.
O-glycan repertoires on a mucin-type reporter protein expressed in CHO cell pools transiently transfected with O-glycan core enzyme cDNAs
J. Biotechnol.
199
77-89
2015
Homo sapiens (Q02742)
brenda
Lete, C.; Markine-Goriaynoff, N.; Machiels, B.; Pang, P.C.; Xiao, X.; Canis, K.; Suzuki, M.; Fukuda, M.; Dell, A.; Haslam, S.M.; Vanderplasschen, A.; Gillet, L.
Bovine herpesvirus 4 modulates its beta-1,6-N-acetylglucosaminyltransferase activity through alternative splicing
J. Virol.
90
2039-2051
2015
Bovine gammaherpesvirus 4 (Q9IZK2), Bovine gammaherpesvirus 4 V. test (Q9IZK2)
brenda
Kojima, Y.; Yoneyama, T.; Hatakeyama, S.; Mikami, J.; Sato, T.; Mori, K.; Hashimoto, Y.; Koie, T.; Ohyama, C.; Fukuda, M.; Tobisawa, Y.
Detection of core2 beta-1,6-N-acetylglucosaminyltransferase in post-digital rectal examination urine is a reliable indicator for extracapsular extension of prostate cancer
PLoS ONE
10
e0138520
2015
Homo sapiens
brenda
Tseng, T.H.; Lin, T.W.; Chen, C.Y.; Chen, C.H.; Lin, J.L.; Hsu, T.L.; Wong, C.H.
Substrate preference and interplay of fucosyltransferase 8 and N-acetylglucosaminyltransferases
J. Am. Chem. Soc.
139
9431-9434
2017
Homo sapiens (O95395)
brenda
Lete, C.; Markine-Goriaynoff, N.; Machiels, B.; Pang, P.; Xiao, X.; Canis, K.; Suzuki, M.; Fukuda, M.; Dell, A.; Haslam, S.; Vanderplasschen, A.; Gillet, L.
Bovine herpesvirus 4 modulates its beta-1,6-n-acetylglucosaminyltransferase activity through alternative splicing
J. Virol.
90
2039-2051
2016
Bovine gammaherpesvirus 4
brenda
Mardahl, M.; Schroeter, M.F.; Engelbert, D.; Pink, M.; Sperandio, M.; Hamann, A.; Syrbe, U.
Core 2 beta1,6-N-acetylglucosaminyltransferase-I, crucial for P-selectin ligand expression is controlled by a distal enhancer regulated by STAT4 and T-bet in CD4+ T helper cells 1
Mol. Immunol.
77
132-140
2016
Homo sapiens (Q02742)
brenda
Sumardika, I.W.; Youyi, C.; Kondo, E.; Inoue, Y.; Ruma, I.M.W.; Murata, H.; Kinoshita, R.; Yamamoto, K.I.; Tomida, S.; Shien, K.; Sato, H.; Yamauchi, A.; Futami, J.; Putranto, E.W.; Hibino, T.; Toyooka, S.; Nishibori, M.; Sakaguchi, M.
beta-1,3-Galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 increases MCAM stability, which enhances S100A8/A9-mediated cancer motility
Oncol. Res.
26
431-444
2018
Homo sapiens (O95395), Homo sapiens
brenda
Fernandez, L.P.; Sanchez-Martinez, R.; Vargas, T.; Herranz, J.; Martin-Hernandez, R.; Mendiola, M.; Hardisson, D.; Reglero, G.; Feliu, J.; Redondo, A.; Ramirez de Molina, A.
The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance
Sci. Rep.
8
8485
2018
Homo sapiens (O95395), Homo sapiens
brenda
Liu, J.; Zhang, Y.; Liu, W.; Zhang, Q.; Xiao, H.; Song, H.; Luo, B.
MiR-BART1-5p targets core 2beta-1,6-acetylglucosaminyltransferase GCNT3 to inhibit cell proliferation and migration in EBV-associated gastric cancer
Virology
541
63-74
2020
Homo sapiens (O95395), Homo sapiens
brenda
Select items on the left to see more content.
EXTERNAL LINKS (specific for EC-Number 2.4.1.102)
html completed
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
